Anti-LGI4/ AMCNMY/ LGIL3 functional antibody

Anti-LGI4/ AMCNMY/ LGIL3 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to LGI4/LGI4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1071-Ab-1/ GM-Tg-hg-SE1071-Ab-2Anti-Human LGI4 monoclonal antibodyHuman
GM-Tg-rg-SE1071-Ab-1/ GM-Tg-rg-SE1071-Ab-2Anti-Rat LGI4 monoclonal antibodyRat
GM-Tg-mg-SE1071-Ab-1/ GM-Tg-mg-SE1071-Ab-2Anti-Mouse LGI4 monoclonal antibodyMouse
GM-Tg-cynog-SE1071-Ab-1/ GM-Tg-cynog-SE1071-Ab-2Anti-Cynomolgus/ Rhesus macaque LGI4 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1071-Ab-1/ GM-Tg-felg-SE1071-Ab-2Anti-Feline LGI4 monoclonal antibodyFeline
GM-Tg-cang-SE1071-Ab-1/ GM-Tg-cang-SE1071-Ab-2Anti-Canine LGI4 monoclonal antibodyCanine
GM-Tg-bovg-SE1071-Ab-1/ GM-Tg-bovg-SE1071-Ab-2Anti-Bovine LGI4 monoclonal antibodyBovine
GM-Tg-equg-SE1071-Ab-1/ GM-Tg-equg-SE1071-Ab-2Anti-Equine LGI4 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1071-Ab-1/ GM-Tg-hg-SE1071-Ab-2; GM-Tg-rg-SE1071-Ab-1/ GM-Tg-rg-SE1071-Ab-2;
GM-Tg-mg-SE1071-Ab-1/ GM-Tg-mg-SE1071-Ab-2; GM-Tg-cynog-SE1071-Ab-1/ GM-Tg-cynog-SE1071-Ab-2;
GM-Tg-felg-SE1071-Ab-1/ GM-Tg-felg-SE1071-Ab-2; GM-Tg-cang-SE1071-Ab-1/ GM-Tg-cang-SE1071-Ab-2;
GM-Tg-bovg-SE1071-Ab-1/ GM-Tg-bovg-SE1071-Ab-2; GM-Tg-equg-SE1071-Ab-1/ GM-Tg-equg-SE1071-Ab-2
Products NameAnti-LGI4 monoclonal antibody
Formatmab
Target NameLGI4
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LGI4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1071-Ag-1Recombinant multi-species LGI4/ AMCNMY/ LGIL3 protein


    Target information

    Target IDGM-SE1071
    Target NameLGI4
    Gene ID163175,243914,361549,718426,484582,101080343,618195,100050571
    Gene Symbol and SynonymsAMC1,AMCNMY,clp,LGI4,LGIL3
    Uniprot AccessionQ8N135
    Uniprot Entry NameLGI4_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000153902
    Target ClassificationN/A

    The target: LGI4, gene name: LGI4, also named as AMCNMY, LGIL3. Involved in regulation of myelination. Predicted to be located in extracellular region. Predicted to be active in extracellular space. Implicated in arthrogryposis multiplex congenita-1 and childhood absence epilepsy. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.